TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Problems
Androgens in postmenopausal women
Key Statistics
- 5% — Female testosterone vs male levels
- 300 µg/day — Effective testosterone patch dose
- 5 mg/day — Typical UK off-label gel dose
Don't-miss facts
-
Only evidence-based indication for postmenopausal testosterone is HSDD — not mood, energy, cognition, bone or muscle
-
NICE NG23: consider testosterone if estrogen therapy alone is ineffective for low sexual desire
-
Diagnose HSDD clinically: distressing symptoms ≥6 months, ≥75% of sexual encounters — testosterone levels do not diagnose it
-
Check total testosterone before starting and at 2–3 months (BMS 2022); do not measure free testosterone
-
Prescribe non-oral (transdermal) only; oral testosterone raises LDL and lowers HDL. Usual off-label dose 5 mg/day; effective patch dose 300 µg/day
-
Apply to clean dry lower abdomen/upper thigh, avoid skin contact with others until dry, wash hands after
-
Allow ≥8 weeks for response; trial 3 months minimum, stop at 6 months if no improvement; review annually
-
Avoid: acute liver disease, competitive athletes, upper-normal/high baseline testosterone; do not use DHEA, tibolone or compounded testosterone for HSDD
Evidence at a glance
Proven: transdermal testosterone for HSDD Not proven: cognition, mood, bone, lean mass
Not recommended: oral testosterone, DHEA, tibolone, compounded
Key trial numbers
APHRODITE (n=814, no estrogen): 300 µg/day +2.1 vs +0.7 satisfying episodes/month (p<0.001); 150 µg/day NS ADORE (n=272, natural menopause): +1.69 vs +0.53/month (p=0.0089) Hair growth RR 1.69 (1.33–2.14); acne RR 1.46 (1.11–1.92); no virilisation reported with transdermal APHRODITE endometrial: bleeding 10.6% vs 2.6%, no hyperplasia or carcinoma over 52 weeks
Physiology one-liners
Testosterone ~5% of male levels; 100–400 µg/day, 3–4× estrogen output Premenopause: ovary 25% / adrenal 25% / peripheral 50% → at menopause ovary 50% / adrenal 10% / peripheral 40% Bound 66% SHBG, 33% albumin, 1–2% free; FAI = total testosterone × 100 / SHBG Natural menopause does not sharply drop androgens; BSO drops them 50%
Abbreviation Key
- HSDD — hypoactive sexual desire disorder/dysfunction
- DHT — dihydrotestosterone
- FSD — female sexual dysfunction
- SHBG — sex hormone binding globulin
- FSIAD — female sexual interest and arousal disorder
- FAI — free androgen index
- DHEA / DHEA-S — dehydroepiandrosterone / its sulfate
- BMS — British Menopause Society
- NICE — National Institute for Health and Care Excellence
- MHRA — Medicines and Healthcare Products Regulatory Agency
- RCT — randomised controlled trial
- GMC — General Medical Council
- BSO — bilateral salpingo-oophorectomy
- FDA — US Food and Drug Administration
- POI — premature ovarian insufficiency
- DSM — Diagnostic and Statistical Manual of Mental Disorders
- HRT — hormone replacement therapy
- SWAN — Study of Women’s Health Across the Nation
- BMD — bone mineral density
- WHI — Women’s Health Initiative
- CVD — cardiovascular disease
- PGWB — Psychological General Wellbeing index
- HDL / LDL — high-density / low-density lipoprotein
Source: Vigneswaran K, Hamoda H. Androgens in postmenopausal women. The Obstetrician & Gynaecologist 2022;24:228–241. doi:10.1111/tog.12836
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).